


Dermapharm Holding SE



**Investor and Analyst Conference Call
H1 2018**

Grünwald, September 12, 2018

Disclaimer

This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Statements”) reflect various assumptions concerning anticipated results based on Dermapharm’s current business plan or publicly available sources which have not been independently verified or assessed by Dermapharm and which may prove to be incorrect.

The Forward-Looking Statements reflect current expectations based on the current business plan and various other assumptions, involve significant risks and uncertainties, should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of whether or not such results will be achieved. The Forward-Looking Statements only speak as of the date of this publication. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of Dermapharm and the estimates given herein. These factors include those discussed in Dermapharm’s financial statements which are available on Dermapharm’s website. Each recipient of this publication should make its own assessment of the validity of Forward-Looking Statements and other assumptions and, Dermapharm accepts no liability with respect to any Forward-Looking Statements or other assumptions.

Except as provided by law, Dermapharm assumes no obligation whatsoever to update or revise any of the information, Forward-Looking Statements and conclusions contained herein, or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof.

Today's agenda

1. Overview

2. Financial figures H1 2018

3. Outlook FY 2018

Overview


Section 1

Dermapharm – Pharmaceutical excellence “Made in Germany”

A leading German pharmaceutical company...

- Dermapharm is a **leader in branded pharmaceuticals** in selected markets in **Germany** and has an increasing international footprint
- **Flexible** pharmaceutical manufacturing and distribution capabilities with **highly efficient** and **low risk** R&D process based on patent-free APIs resulting in short time-to-market
- **~250** active pharmaceutical ingredients (APIs) and **~950⁽¹⁾** marketing authorizations (MA), which can be partly **leveraged internationally**
- A **top 5** parallel import business in Germany based on revenue
- Continuous **business optimization and growth** through **successful M&A**


...with a highly attractive product portfolio⁽²⁾...



...based on an integrated business model...



...resulting in attractive financials



Dermapharm – The Management Team



Dr. Hans Feldmeier

**Chief Executive
Officer**

15 years company affiliation



Karin Samusch

**Chief Business
Development Officer**

27 years company affiliation



Stefan Grieving

**Chief Marketing
Officer**

8 years company affiliation



Stefan Hümer

**Chief Financial
Officer**

12 years company affiliation

Highlights H1 2018 – Success story with profitable growth continued




Financial figures H1 2018

Section 2

Dermapharm Group Revenue – Driven by significant growth in Branded Pharmaceuticals segment

Dermapharm's revenue development

H1 2017 vs H1 2018 €m, YoY growth (%)



Dermapharm Group

- **Strong revenue growth** of 19.7% to € 280.3 million
- **Main growth drivers:**
 - Successful company acquisitions and integration as well as
 - expansion of the product portfolio through introduction of new, self-developed products in selected markets.

Branded Pharmaceuticals & Other Healthcare Products

- **Revenues significantly up by 48.1%** to € 163.2 million
- Increase from **consolidation of Strathmann and Trommsdorff** and also from **organic growth**


Parallel Import business

- Segment revenues temporarily **decreased by 5.6%** to € 117.1 million.
- Decline mainly due to **concentration on high-margin, but small-volume preparations**

Dermapharm Group EBITDA – Disproportional EBITDA growth, with Group-margin improvement

Dermapharm's EBITDA development

H1 2017 vs H1 2018 €m, YoY growth (%)



Dermapharm Group

- EBITDA growth driven by **Branded Pharmaceuticals**
- **One-time costs of € 1.4 million** for IPO preparations
- **One-time costs of € 2.4 million** for brokerage and consulting in connection with the newly acquired companies Trommsdorff and Strathmann
- **EBITDA up by 29.9%** to € 70.9 million (adjusted) and 22.9% to € 67.1 million (unadjusted)
- **Strong EBITDA margin of 25.3%** (adjusted) and 23.9% (unadjusted)

Branded Pharmaceuticals & Other Healthcare Products

- EBITDA up by **25.7%** to **€ 64.5 million (unadjusted)** and increase mainly based on positive development of gross profit while reducing expenses for SHI rebates and material costs, and
- EBITDA margin of **39.5%** (unadjusted) and below 2017 due to initial consolidation of Strathmann and Trommsdorff


Parallel Import business

- **Disproportional EBITDA growth of 63.1%** to € 5.4 million; EBITDA margin up to **4.6%**
- Growth largely based on **optimization of the product portfolio** and **demand-driven sourcing**
- **Costs were further optimized**

Earnings before tax (EBT) – Reflecting company’s high profitability

Dermapharm’s EBT development

H1 2017 vs H1 2018 €m, YoY growth (%)




Comments

- **EBT increased by 18.0%** to € 52.5 million (unadjusted) resulting in a **margin of 18.7%**
- **Depreciations and amortization at € 12.4 million** and € 5.5 million above the previous year
- **Financial result of € 1.5 million** below previous year’s level of € 1.0 million

Strong Cash flows and cash conversion – Reflecting strong dedication to future growth

Strong cash flow and cash conversion⁽¹⁾

in €m / in % of group EBITDA




Comments

- **CF from operating activities up** due to positive business development
- **CF from investing activities** mainly reflecting M&A
- Strathmann
- Trommsdorff
- **Free cash flow: € -1.7 million** in H1 2018
- **Cash conversion** increased in H1 2018 to **+32.9%**

Balance sheet of Dermapharm Group

Balance Sheet as of 30 June 2018

in €m



Comments


- **Total assets** increased to € 688.4 million
- **Non-current assets** increased mainly due to the increase in intangible assets, Goodwill and Property, plant and equipment
- **Current assets** increased mainly due to higher inventories, trade receivables and other assets
- **Equity** increased to € 217.3 million
- **Current and non-current financial liabilities** amounted to € 218.8 million and € 102.7 million and mainly include
 - Bank loans, and
 - Promissory loans
- **Net debt / unadjusted EBITDA⁽¹⁾**: 1.2x

Outlook FY 2018


Section 3

Dermapharm follows a consequent portfolio strategy

Revenue by market access excl. axicorp⁽¹⁾



MARGIN



Comments

- **Acquisitions** of Trommsdorff, Strathmann, and the hyperthermic devices **further strengthen portfolio shift in H1 2018**
- **Portfolio shift overall leads to**
 - an **increasing share of self-payers products** with strong margins
 - an **increasing share of OTC products**
 - **decreasing dependency** on a highly regulated SHI market
 - **higher independency from SHI rebate contracts** with low margins

Growth strategy – Update on in-house development

H1 2018

Achievements


- All ongoing **development projects on track**
- **Several new products launched in different countries**
 - Germany: Myopridin®, Summavit® materna, Silicea® Nagelaufbauserum, Dekristolvit® 1.000 drops, Verrucutan®, Urocys®, Calcilac mono®, Lactofem Feuchcreme®
 - Austria: Metasol® 16 mg and 32 mg ampoules, Minoxidil® 2% and 5%, Dienovel®, bite away®
 - Poland: Momecutan®
 - Switzerland: Amorocutan Nail lacquer®, bite away®, Herpothem®
 - Croatia: bite away®
 - Ukraine: Dekristol® 4.000



2018

Plans

- **5 RX and OTC products** based on in house development expected to be rolled out as planned
- **More than 40 ongoing development projects** with new products for all product areas
- Out of this product pipeline **28 products to be registered** in the upcoming years in Germany and other European countries
- **Pruritherm® development** and clinical studies



Pruritherm®



Growth strategy – Update on internationalization

H1 2018

Achievements

- **Subsidiaries established** in the UK and Italy (Feb 2018)
- **Sales managers** hired in the UK and Italy
- **Marketing authorizations obtained in EU** for several of recently developed pharmaceuticals
- Scheduled preparation of **European roll-out** of bite away® and Herpothem® and start in own markets
- Numerous **international sales partners** in the field of hyperthermic medical products gained through subsidiary mibeTec GmbH

2018

Plans

- Launch of first products in **UK and Italy**
- Entering **Spain**
- Continuous screening of **international M&A opportunities**
- **International roll-out** of bite away® and Herpothem® in **several countries and regions through different sales channels**



Growth strategy – Update on M&A activities

H1 2018

Achievements

January 2018



- Integration and consolidation of Strathmann and Trommsdorff further **strengthen overall strategy with product portfolio** characterized by:
 - Focus on **niche markets with low competition**
 - Mainly **original products with USPs** focusing on self-payers

2018

Plans

- Integration** of Bio-Diät Berlin, Strathmann and Trommsdorff **on track**:
 - Leveraged product marketing through Dermapharm's existing sales forces
 - Standardization of IT systems
 - Realization of synergies regarding i.e. overhead or sourcing
 - Cost reduction through site selection
- Dermapharm owns the **worldwide marketing rights for bite away® and Herpotherm®** and intends to **market** these devices **globally**
- International roll-out** of bite away® and Herpotherm® in **several counties and regions through different sales channels**



Business update on axicorp Group

H1 2018

Achievements

- Reduction of purchase prices
- Further broadening of sourcing
- Further leverage of the call center
- Sale of bite away® to 6,500 pharmacies via call center

Examples of parallel imported originator-products:



2018

Plans

- Finalization of the falsification guideline project
- Ongoing portfolio optimization
- Launch of additional Dermapharm-OTC products

Leveraging the call center for additional OTC products:



Growth strategy on track and confirming guidance 2018

Revenues 2018

+20% to +25%

- over the previous year (2017: € 467 million)

**EBITDA
2018
(adjusted)**

+22% to +27%

- over the previous year (2017: € 113 million (adjusted))
-


“Growth rates based on organic growth and the four acquisitions 2017/18, which are included in the forecast.”

Investor contact

cometis AG
Claudius Krause

E-Mail: ir@dermapharm.de
Phone: +49 (0) 611 20 58 55 28

Dermapharm Holding SE



**Becoming the leading European pharmaceuticals
manufacturer in selected markets**